Advertisement

ADVERTISEMENT

Jordan Kadish

News
Valemetostat Among Patients With R/R Aggressive Adult T-Cell Leukemia/Lymphoma
05/08/2023
According to findings from a phase 2 trial, valemetostat demonstrated promising efficacy and tolerability among patients with R/R aggressive adult T-cell leukemia/lymphoma, achieving a high overall response rate and a manageable safety...
According to findings from a phase 2 trial, valemetostat demonstrated promising efficacy and tolerability among patients with R/R aggressive adult T-cell leukemia/lymphoma, achieving a high overall response rate and a manageable safety...
According to findings from a...
05/08/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Patients With BCL2/MYC High-Expressing Non-GCB DLBCL May Be Preferentially Responsive to BTK Inhibitor Ibrutinib Plus R-CHOP Regimen
08/02/2023
Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.
Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.
Patients with high BCL2/MYC...
08/02/2023
Oncology
News
Low-Dose Splenic Radiotherapy Demonstrates Feasibility, Safety in Combination With AlloHSCT Among Patients With Myelofibrosis
10/10/2023
Low-dose splenic radiotherapy combined with allogeneic hematopoietic stem cell transplantation demonstrated encouraging safety outcomes and may lead to improvement in splenomegaly and among patients with myelofibrosis, according to a...
Low-dose splenic radiotherapy combined with allogeneic hematopoietic stem cell transplantation demonstrated encouraging safety outcomes and may lead to improvement in splenomegaly and among patients with myelofibrosis, according to a...
Low-dose splenic radiotherapy...
10/10/2023
Oncology
News
Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis
01/22/2024
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment...
01/22/2024
Oncology
News
Lintuzumab-Ac225 With Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML
02/10/2023
A phase 1 study found that the combination of Actimab-A (Lintuzumab-Ac225) and CLAG-M for patients with R/R AML with adverse features yielded a high response rate and MRD negativity.
A phase 1 study found that the combination of Actimab-A (Lintuzumab-Ac225) and CLAG-M for patients with R/R AML with adverse features yielded a high response rate and MRD negativity.
A phase 1 study found that the...
02/10/2023
Oncology
News
Gilteritinib Treatment in Real-World Setting Among Patients With R/R AML
04/25/2023
According to findings from a multicohort trial, the efficacy of real-world gilteritinib treatment for patients with R/R AML was consistent with results of the past ADMIRAL trial, making it a viable treatment option.
According to findings from a multicohort trial, the efficacy of real-world gilteritinib treatment for patients with R/R AML was consistent with results of the past ADMIRAL trial, making it a viable treatment option.
According to findings from a...
04/25/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology
News
Upfront High-Dose Chemotherapy Followed by Auto-HSCT Improved Prognosis Among Patients With High-Intermediate/High-Risk Stage IV DLBCL
07/27/2023
Upfront chemotherapy followed by autologous hematopoietic stem-cell transplantation yielded effective results among patients with intermediate/high-risk stage IV DLBCL not otherwise specified, according to a retrospective cohort study.
Upfront chemotherapy followed by autologous hematopoietic stem-cell transplantation yielded effective results among patients with intermediate/high-risk stage IV DLBCL not otherwise specified, according to a retrospective cohort study.
Upfront chemotherapy followed by...
07/27/2023
Oncology
News
CLIA Chemotherapy With or Without Sorafenib as Frontline Treatment for Patients With AML
11/20/2023
According to a phase 2 trial, cladribine, idarubicin, and intermediate-dose cytarabine standard chemotherapy with or without sorafenib yielded encouraging efficacy as a frontline treatment for patients with various subsets of acute myeloid...
According to a phase 2 trial, cladribine, idarubicin, and intermediate-dose cytarabine standard chemotherapy with or without sorafenib yielded encouraging efficacy as a frontline treatment for patients with various subsets of acute myeloid...
According to a phase 2 trial,...
11/20/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use